Indira Guleria

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc A critical role for the programmed death ligand 1 in fetomaternal tolerance
    Indira Guleria
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 202:231-7. 2005
  2. pmc Tissue expression of PD-L1 mediates peripheral T cell tolerance
    Mary E Keir
    Department of Pathology, Brigham and Women s Hospital and Children s Hospital Boston, MA 02115, USA
    J Exp Med 203:883-95. 2006
  3. ncbi request reprint Maternal acceptance of the fetus: true human tolerance
    Indira Guleria
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 178:3345-51. 2007
  4. doi request reprint Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy
    Jun Yang
    Transplantation Research Center, Brigham and Women s Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
    Circulation 117:660-9. 2008
  5. ncbi request reprint A link between PDL1 and T regulatory cells in fetomaternal tolerance
    Antje Habicht
    Transplantation Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 179:5211-9. 2007
  6. ncbi request reprint Mechanisms of PDL1-mediated regulation of autoimmune diabetes
    Indira Guleria
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Clin Immunol 125:16-25. 2007
  7. pmc Divergent role of donor dendritic cells in rejection versus tolerance of allografts
    Takuya Ueno
    Transplantation Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Am Soc Nephrol 20:535-44. 2009
  8. pmc Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, and Transplantation Research Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Exp Med 203:2737-47. 2006
  9. pmc Targeting CD22 reprograms B-cells and reverses autoimmune diabetes
    Paolo Fiorina
    Transplantation Research Center, Children s Hospital and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes 57:3013-24. 2008
  10. ncbi request reprint Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice
    Mohammed Javeed I Ansari
    Transplantation Research Center, Renal Division, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Clin Immunol 126:140-7. 2008

Collaborators

Detail Information

Publications17

  1. pmc A critical role for the programmed death ligand 1 in fetomaternal tolerance
    Indira Guleria
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 202:231-7. 2005
    ..These results provide the first evidence that PDL1 is involved in fetomaternal tolerance...
  2. pmc Tissue expression of PD-L1 mediates peripheral T cell tolerance
    Mary E Keir
    Department of Pathology, Brigham and Women s Hospital and Children s Hospital Boston, MA 02115, USA
    J Exp Med 203:883-95. 2006
    ..These data provide evidence that PD-L1 expression on parenchymal cells rather than hematopoietic cells protects against autoimmune diabetes and point to a novel role for PD-1-PD-L1 interactions in mediating tissue tolerance...
  3. ncbi request reprint Maternal acceptance of the fetus: true human tolerance
    Indira Guleria
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 178:3345-51. 2007
    ....
  4. doi request reprint Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy
    Jun Yang
    Transplantation Research Center, Brigham and Women s Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
    Circulation 117:660-9. 2008
    ..We investigated the role of recipient versus donor PD-1 ligands in the pathogenesis of allograft rejection with emphasis on the role of tissue expression in regulating this alloimmune response in vivo...
  5. ncbi request reprint A link between PDL1 and T regulatory cells in fetomaternal tolerance
    Antje Habicht
    Transplantation Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 179:5211-9. 2007
    ..This is the first report providing evidence for a link between PDL1 and T regulatory cells in mediating fetomaternal tolerance...
  6. ncbi request reprint Mechanisms of PDL1-mediated regulation of autoimmune diabetes
    Indira Guleria
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Clin Immunol 125:16-25. 2007
    ..These data provide strong evidence that PDL1 regulates autoimmune diabetes by limiting the expansion of CD4+ and CD8+ autoreactive T cells, and define the timing and locale of PDL1-mediated regulation of type 1 diabetes...
  7. pmc Divergent role of donor dendritic cells in rejection versus tolerance of allografts
    Takuya Ueno
    Transplantation Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Am Soc Nephrol 20:535-44. 2009
    ..These data indicate the importance of the CX3CR1 pathway in the generation of heart tissue dendritic cells and the divergent role of tissue/dendritic cells in rejection versus tolerance...
  8. pmc Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, and Transplantation Research Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Exp Med 203:2737-47. 2006
    ....
  9. pmc Targeting CD22 reprograms B-cells and reverses autoimmune diabetes
    Paolo Fiorina
    Transplantation Research Center, Children s Hospital and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes 57:3013-24. 2008
    ..To investigate a B-cell-depleting strategy to reverse diabetes in naïve NOD mice...
  10. ncbi request reprint Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice
    Mohammed Javeed I Ansari
    Transplantation Research Center, Renal Division, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Clin Immunol 126:140-7. 2008
    ..We conclude that in islet transplantation and autoimmune diabetes, ICOS blockade can be effective in inhibiting alloimmunity and preventing autoimmunity but is ineffective in inhibiting recurrence of autoimmunity...
  11. pmc The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance
    Francesca D'Addio
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School Renal Division, Boston, MA 02115, USA
    J Immunol 187:4530-41. 2011
    ..This is to our knowledge the first report using an alloantigen-specific model that establishes a link between PDL1, Th17 cells, and fetomaternal tolerance...
  12. ncbi request reprint Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis
    Bing Zhu
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 176:3480-9. 2006
    ..In conclusion, PD-L1 and PD-L2 differentially regulate the susceptibility and chronic progression of EAE in a strain-specific manner...
  13. pmc Anti-CD3 mAb treatment cures PDL1-/-.NOD mice of diabetes but precipitates fatal myocarditis
    Bechara Mfarrej
    Transplantation Research Center, Brigham and Women s Hospital and Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Clin Immunol 140:47-53. 2011
    ..NOD mice as the mice develop T1D at an early age and die from diabetes prior to manifesting other autoimmune diseases...
  14. pmc B7h (ICOS-L) maintains tolerance at the fetomaternal interface
    Leonardo V Riella
    Transplantation Research Center, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Pathol 182:2204-13. 2013
    ..Taken together, these data support the hypothesis that B7h blockade abrogates tolerance at the fetomaternal interface by enhancing CD8(+) effector response and reducing local immunomodulation mediated by CD8(+) regulatory T cells...
  15. pmc TIM-3 regulates innate immune cells to induce fetomaternal tolerance
    Lola Chabtini
    Transplantation Research Center, Brigham and Women s Hospital and Boston Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 190:88-96. 2013
    ..These data highlight the interplay between cells of the innate immune system at the FMI and their influence on successful pregnancy in mice...
  16. pmc Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis
    Bing Zhu
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Immunol 142:351-61. 2012
    ..In summary, our study demonstrates that LNFPIII glycan treatment suppresses EAE by modulating both innate and T cell immune response...
  17. doi request reprint The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome
    Stefan G Tullius
    Division of Transplant Surgery, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Ann Surg 252:662-74. 2010
    ..To evaluate the interaction of donor and recipient age on transplant outcome and immune response...